Orqis Medical Corporation CEO To Present At Jefferies Life Sciences Conference June 27 In New York City
LAKE FOREST, Calif., June 20 /PRNewswire/ -- Orqis Medical Corporation announced today that Ken Charhut, President and Chief Executive Officer, will present an overview of the company's progress in developing its proprietary devices to treat acutely decompensated and chronic heart failure at the upcoming Jefferies Life Sciences Conference.
The presentation will begin at 8:30 a.m. (ET) on Tuesday, June 27, 2006 and will be followed by a series of one-on-one investor meetings. The conference will be held at the Mandarin Oriental Hotel in New York. An audio webcast of the presentation, both live and replay, will be accessible at www.jefferies.com.
About Orqis Medical Corporation
Orqis Medical Corporation is a privately held, clinical-stage medical device company seeking to redefine heart failure therapy by developing products that prevent or reverse underlying disease progression and provide new treatment options to the clinical community to improve patient outcomes and quality of life.
The company's percutaneous Cancion(R) System, for the treatment of acutely decompensated heart failure is CE marked and is currently under an investigational device exemption (IDE) investigation in the United States in the pivotal MOMENTUM Trial. The company's implantable Exeleras(R) System, about the size of an implantable cardiac defibrillator (ICD), is designed to treat mid- to late-stage chronic heart failure patients. First clinical use of this system is planned for the first half of 2007. For more information on Orqis Medical, please visit: www.orqis.com and for the MOMENTUM Trial, please visit: www.momentumtrial.com.
NOTE: Orqis, Cancion, and Exeleras are among the trademarks or registered trademarks of Orqis Medical Corporation.
Orqis Medical CorporationCONTACT: Brian McIntee, Director of Marketing, +1-949-268-0184, or John M.Markovich, Chief Financial Officer, +1-949-268-0552, both of Orqis